Levocabastine nasal spray significantly improves perennial allergic rhinitis: a single-blind placebo-controlled study

Auris Nasus Larynx. 2010 Aug;37(4):436-42. doi: 10.1016/j.anl.2009.11.014. Epub 2010 Feb 6.

Abstract

Objective: The efficacy of levocabastine nasal spray for relieving the symptoms of perennial allergic rhinitis was compared with placebo in a single-blind study.

Methods: Three hundred and thirty-five patients with moderate to severe perennial allergic rhinitis were randomized to three groups that were administered a high or low dose of levocabastine nasal spray or a placebo. Patients were not informed of their treatment. Efficacy was evaluated based on the changes of symptoms and rhinoscopy findings.

Results: Significant improvement of symptoms was observed in both the high-dose and low-dose levocabastine groups compared with the placebo group. There were no significant differences of efficacy between the high-dose and low-dose levocabastine groups. There was also no significant difference in the occurrence of adverse effects among the three groups.

Conclusion: Levocabastine nasal spray is a safe and effective treatment for perennial allergic rhinitis.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Adult
  • Female
  • Histamine H1 Antagonists, Non-Sedating / administration & dosage
  • Histamine H1 Antagonists, Non-Sedating / therapeutic use*
  • Humans
  • Male
  • Nasal Obstruction / drug therapy
  • Rhinitis, Allergic, Perennial / drug therapy*
  • Single-Blind Method
  • Treatment Outcome

Substances

  • Histamine H1 Antagonists, Non-Sedating